Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer

BRCAness Predicts Resistance to Taxane-Containing Regimens in Triple Negative Breast Cancer During Neoadjuvant Chemotherapy

(2015) Sadako Akashi-Tanaka et al.   Clinical Breast Cancer

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms

(2015) Philip C. Schouten et al.   Molecular Oncology

c-Myc Suppression of DNA Double-strand Break Repair

(2015) Zhaozhong Li et al.   NEOPLASIA

MicroRNA signatures in hereditary breast cancer

(2013) Rosa Murria Estal et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

(2013) E H Lips et al.   BRITISH JOURNAL OF CANCER

DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows

(2013) Maria D. Paraskevopoulou et al.   NUCLEIC ACIDS RESEARCH

Differential Chemotherapeutic Sensitivity for Breast Tumors With "BRCAness": A Review

(2013) P. Chalasani et al.   ONCOLOGIST

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients

(2011) R. Ben Gacem et al.   Cancer Epidemiology

Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer

(2011) Cathy B Moelans et al.   JOURNAL OF PATHOLOGY

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

(2010) M. A. Vollebergh et al.   ANNALS OF ONCOLOGY

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy

(2010) E. H. Lips et al.   ANNALS OF ONCOLOGY

Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup

(2009) M. Chehani Alles et al.   PLoS One

A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response

(2009) Sanjay Chandriani et al.   PLoS One

High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations

(2008) Inmaculada de Juan et al.   BREAST CANCER RESEARCH AND TREATMENT

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH

(2008) Simon A. Joosse et al.   BREAST CANCER RESEARCH AND TREATMENT

Mutaciones de BRCA1 y BRCA2 en familias estudiadas en el Programa de Consejo Genético en el Cáncer de la Comunidad Valenciana

(2008) Eva Esteban Cardeñosa et al.   MEDICINA CLINICA

The Molecular Pathology of Hereditary Breast Cancer

(2008) J. Palacios et al.   PATHOBIOLOGY

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA